Claims for Patent: 9,636,385

Summary for Patent: 9,636,385

Title:	Use of collagenase to treat glaucoma
Abstract:	Provided is a method of treatment for reducing fibrosis involving administering purified collagenase into an anterior chamber of an eye of a human patient.
Inventor(s):	Honkanen; Robert (Sound Beach, NY)
Assignee:	The Research Foundation for The State University of New York (Albany, NY)
Application Number:	14/438,385
Patent Claims:	1. A method for treating or reducing fibrosis in a subject undergoing glaucoma surgery, the method comprising: administering an effective amount of purified collagenase into an anterior segment of an eye by injection to said subject, wherein the effective amount of purified collagenase is administered in conjunction with fluorescein dye, wherein the effective amount of purified collagenase is administered before the glaucoma surgery, and wherein the purified collagenase is injected in a dose of at least about 15,000 SRC units/mg. 2. The method of claim 1, wherein the anterior segment is a sub-Tenons space of the eye. 3. The method of claim 1, wherein the purified collagenase is Clostridiopeptidase A derived from bacterium Clostridium histolyticum. 4. The method of claim 1, wherein purified collagenase is administered in an absence of triamcinolone or other corticosteroids. 5. The method of claim 1, wherein the purified collagenase comprises one of collagenase I and collagenase II.

Details for Patent 9,636,385

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2032-10-24